An interventional study of Endovascular Aneurysm Repair with Physician Modified Endograft in Juxtarenal Abdominal Aortic Aneurysm, sponsored by Cali Johnson. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-15.
Sponsored by Cali Johnson · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 122 studies in Aortic Aneurysm, Abdominal with a site in United States — 28 open to participants now, 34 under way, 1 of them phase 3. Aortic Aneurysm, Abdominal · United States.
Among the 122 studies in Aortic Aneurysm, Abdominal with a site in United States, this one is the 73rd largest by planned enrollment of the 85 interventional ones that give a count, is one of 4 that started in 2025, is one of 64 with no phase, reaches primary completion later than 15 of the 33 other live ones, and was the 118th registered.
467 studies on the registry are indexed under Aortic Aneurysm, Abdominal; 99 are open to participants now.
Browse Aortic Aneurysm, Abdominal studies →28 of the 122 studies in Aortic Aneurysm, Abdominal with a site in United States are open now. Recruiting first, the newest first:
University of Pennsylvania · Sites in United States
Ages 18+ · Healthy volunteers
Aiatella Oy · Sites in United States, Brazil
Ages 22+ · Healthy volunteers
Washington University School of Medicine · Sites in United States
Ages 18+ · Healthy volunteers
Steven Maximus · Sites in United States
Ages 18+
W.L.Gore & Associates · Sites in United States, Australia, Austria and 10 more countries
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 66 Aortic Aneurysm, Abdominal studies recruiting now, 52 (79%) set no upper age limit and 3 (5%) stop at 75 or younger; 2 take children under 18; 8 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
122 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 8 · Phase 3 2 · Phase 4 4
First in 1998; this study’s year is marked. 4 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 15 is below the median of 66 across 228 interventional studies indexed under Aortic Aneurysm, Abdominal.
Median enrollment 94 across the 85 interventional studies, 210 across the 32 observational. Of the 74 that completed or were terminated, 39 (53%) have results posted.
This tab as a report to print or save as PDF → With an account.
63 of 122 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Cali Johnson as lead sponsor.
Cali Johnson has 1 study filed under Aortic Aneurysm, Abdominal — fewer than ten, so there is no comparison to draw.
9 of the studies in Aortic Aneurysm, Abdominal with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04875429Cook Research IncorporatedZenith® Fenestrated+ Clinical Study | 2026-11 |
| NCT03446287Mayo ClinicClinical Outcomes of Patients Treated With Open Surgical Repair for Complex Aortic Aneurysms | 2026-12 |
| NCT05004051ViTAA Medical SolutionsViTAA Registry Pre- and Post-Operative Monitoring for Endovascular Aortic Aneurysm Repair and Serial Monitoring for AAA | 2026-12-31 |
| NCT07473102Washington University School of MedicinePET Imaging of MMP Activation in AAA: Clinical Component | 2027-03-31 |
| NCT06990048EndologixThe Long-Term EVAR Assessment and Follow-Up (LEAF) Study for the AFX2 System | 2027-05 |
Add all 9 to your calendar (.ics) → With an account.
Among the 122 studies in Aortic Aneurysm, Abdominal with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to assess the effects of a physician-modified endovascular graft (PMEG) for juxtarenal aortic aneurysms by collecting data on its performance. Participants in the study will undergo surgery to repair their juxtarenal aortic aneurysm using the PMEG device. After the surgery, participants will attend several follow-up visits to monitor their recovery and the device's effectiveness. These follow-up visits will take place at hospital discharge, then at 1 month, 6 months, 12 months, and once a year for up to 5 years after surgery.
A juxtarenal aortic aneurysm is an aneurysm that occurs near the renal arteries, which bring blood to the kidneys. This research study will evaluate if the physician-modified endovascular graft (PMEG) is safe and effective in the treatment of juxtarenal aortic aneurysms. The PMEG device is an investigational device, which means it has not been approved by the FDA. The device is designed to create a pathway through the aneurysm for blood flow to the arteries, reducing the blood pressure that the aneurysm experiences. There are several types of endovascular devices depending on how big the aneurysm is, where the aneurysm is located in relation to the kidney, or other physical measurements of the blood vessels. The upper portion of the device, or stent graft, will include between one and four holes (fenestrations). The holes allow the device to be located above the renal arteries (the blood vessels that supply blood to the kidneys) without blocking the blood flow to them. Smaller grafts are then placed in the blood vessels to the kidneys, the intestines, and liver to be connected to the main aortic graft, allowing blood to flow to the organs.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patient has a juxtarenal abdominal aortic aneurysm that meets at least one of the following:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Surgical procedure to repair the juxtarenal abdominal aortic aneurysm, during which the physician-modified endovascular graft (PMEG) device will be used.
Device: Endovascular Aneurysm Repair with Physician Modified Endograft
The surgeon will make an incision to access the femoral artery and insert a thin wire to guide the catheter to the juxtarenal aortic aneurysm. The main graft will be modified by hand to match the participant's anatomy, then reloaded and guided through the artery to the aorta. Once in place, the graft will be deployed, and additional stents will be inserted into vital arteries that supply the kidneys and bowels. Two smaller grafts will be placed into the iliac arteries.This allows blood to flow to the target organs and legs, protecting the aneurysm from rupture. All catheters will then be removed, leaving the graft in place, and the incisions will be closed.
All Cause Mortality
The primary safety endpoint is defined as the proportion of subjects who experience a Major Adverse Event (MAE) within 30 days of the index procedure, including all-cause mortality.
Time frame: 30 days post index procedure
Myocardial Infarction
The primary safety endpoint is defined as the proportion of subjects who experience a Major Adverse Event (MAE) within 30 days of the index procedure, including myocardial infarction.
Time frame: 30 days post index procedure
Stroke
The primary safety endpoint is defined as the proportion of subjects who experience a Major Adverse Event (MAE) within 30 days of the index procedure, including stroke.
Time frame: 30 days post index procedure
Renal Failure
The primary safety endpoint is defined as the proportion of subjects who experience a Major Adverse Event (MAE) within 30 days of the index procedure, including renal failure.
Time frame: 30 days post index procedure
Respiratory Failure
The primary safety endpoint is defined as the proportion of subjects who experience a Major Adverse Event (MAE) within 30 days of the index procedure, including respiratory failure.
Time frame: 30 days post index procedure
Paraplegia
The primary safety endpoint is defined as the proportion of subjects who experience a Major Adverse Event (MAE) within 30 days of the index procedure, including paraplegia.
Time frame: 30 days post index procedure
Bowel Ischemia
The primary safety endpoint is defined as the proportion of subjects who experience a Major Adverse Event (MAE) within 30 days of the index procedure, including bowel ischemia.
Time frame: 30 days post procedure
Procedural Blood Loss (>1000 cc)
The primary safety endpoint is defined as the proportion of subjects who experience a Major Adverse Event (MAE) within 30 days of the index procedure, including procedural blood loss (\>1000 cc).
Time frame: 30 days post procedure
Treatment Success
The primary effectiveness endpoint is the proportion of subjects that achieve Treatment Success. Treatment Success is a composite endpoint assessed at 12 months that requires the following criteria to be met: Technical Success (at the index procedure) is defined by the following: 1. The physician was able to insert the delivery catheter and deliver the physician modified endovascular graft to the treatment site and preserve blood flow into the vessels intended to have blood flow preserved. 2. Freedom from Type I \& III endoleaks at 12 months 3. Freedom from stent graft migration at 12 months 4. Freedom from aortic aneurysm enlargement at 12 months 5. Freedom from aortic aneurysm rupture and conversion to open repair through 12 months
Time frame: 12 months post index procedure
Mortality
Secondary safety endpoints will be evaluated at 30 days, 6 months, \& 12 months following the initial implant procedure and annually through 5 years, including mortality.
Time frame: 30 days, 6 months, and annually through 5 years post index procedure
Aneurysm related mortality
Secondary safety endpoints will be evaluated at 30 days, 6 months, \& 12 months following the initial implant procedure and annually through 5 years, including aneurysm related mortality.
Time frame: 30 days, 6 months, and annually through 5 years post index procedure
Aneurysm Rupture
Secondary safety endpoints will be evaluated at 30 days, 6 months, \& 12 months following the initial implant procedure and annually through 5 years, including aneurysm rupture.
Time frame: 30 days, 6 months, and annually through 5 years post index procedure.
Major Adverse Events (MAE)
Secondary safety endpoints will be evaluated at 30 days, 6 months, \& 12 months following the initial implant procedure and annually through 5 years, including major adverse events.
Time frame: 30 days, 6 months, and annually through 5 years post index procedure
Renal failure with or without permanent dialysis
Secondary safety endpoints will be evaluated at 30 days, 6 months, \& 12 months following the initial implant procedure and annually through 5 years, including renal failure with or without permanent dialysis.
Time frame: 30 days, 6 months, and annually through 5 years post index procedure.
Graft Infection
Secondary safety endpoints will be evaluated at 30 days, 6 months, \& 12 months following the initial implant procedure and annually through 5 years, including graft infection.
Time frame: 30 days, 6 months, and annually through 5 years post index procedure.
Technical Success
Secondary effectiveness endpoints will be evaluated including technical success. Technical Success (evaluated at 30-days) is a composite of the following: a. Successful access to the arterial system using remote arterial exposure, percutaneous technique, or open surgical conduits; b. Successful delivery and deployment at the intended implantation site; c. Successful side branch catheterization and placement of bridging stents with restoration and maintenance of flow in all intended target vessels; d. Successful withdrawal of the delivery system; e. Patency of all endovascular graft and stent components; f. Absence of device deformations requiring unplanned placement of an additional device; g. Absence of Type I and III endoleaks at completion angiography that extends beyond 30 days by confirmatory imaging
Time frame: 30 days, 6 months, and annually through 5 years post index procedure
Stent graft migration > 10 mm
Secondary effectiveness endpoints will be evaluated including stent graft migration \> 10 mm.
Time frame: 30 days, 6 months, and annually through 5 years post index procedure.
All endoleaks
Secondary effectiveness endpoints will be evaluated including all endoleaks.
Time frame: 30 days, 6 months, and annually through 5 years post index procedure.
AAA enlargement
Secondary effectiveness endpoints will be evaluated including AAA enlargement.
Time frame: 30 days, 6 months, and annually through 5 years post index procedure.
Patency related events
Secondary effectiveness endpoints will be evaluated including patency related events.
Time frame: 30 days, 6 months, and annually through 5 years post index procedure.
Device integrity failure
Secondary effectiveness endpoints will be assessed including device integrity failure.
Time frame: 30 days, 6 months, and annually through 5 years post index procedure.
Conversion to open repair
Secondary effectiveness endpoints will be evaluated including conversion to open repair.
Time frame: 30 days, 6 months, and annually through 5 years post index procedure.
Secondary Intervention
Secondary effectiveness endpoints will be evaluated including secondary interventions.
Time frame: 30 days, 6 months, and annually through 5 years post index procedure.
Plan to share: Undecided
No publications or documents are linked to this record.
Started May 2025 (actual). Primary completion is estimated for Aug 2027, 26 months after the start.
Of 51 non-industry interventional studies with no phase under Aortic Aneurysm, Abdominal, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 61. This study's planned 26 months is below that.
Counting every sponsor, half of 94 studies reached it within 43 months; a quarter within 23 and three quarters within 65.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.